These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37932988)

  • 21. Effect of
    Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
    Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
    Li X; Pasche B; Zhang W; Chen K
    JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
    Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
    Front Immunol; 2022; 13():906889. PubMed ID: 35757722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.
    Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
    Cancer Cell Int; 2021 Apr; 21(1):219. PubMed ID: 33858449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma.
    Yang S; Chen S; Zhao Y; Wu T; Wang Y; Li T; Fu L; Ye T; Hu YQ; Chen H
    Thorac Cancer; 2023 Nov; 14(33):3295-3308. PubMed ID: 37795779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
    Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
    J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring
    Wang Q; Yang Y; Yang M; Li X; Chen K
    Aging (Albany NY); 2020 Jun; 12(11):10827-10843. PubMed ID: 32491995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
    Li Z; Wang W; Wu J; Ye X
    Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Association of
    Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
    Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.